摘要
目的:评价3种用药方案治疗幽门螺杆菌(Hp)感染的成本-效果。方法:441例Hp感染的消化性溃疡患者随机分为3组,分别服用雷贝拉唑+克拉霉素+阿莫西林(A组)、奥美拉唑+克拉霉素+替硝唑(B组)、奥美拉唑+克拉霉素+阿莫西林(C组),各组疗程均为1周,观察疗效并进行成本-效果分析。结果:A、B、C组成本分别为325.04、221.30、211.64元,Hp根除率分别为92.2%、89.2%、79.1%,成本-效果比分别为352.54、248.09、267.56;A、B方案相对于C方案的增量成本-效果比分别为865.65、95.64。结论:B方案治疗幽门螺杆菌感染较为经济、合理。
OBJECTIVE：To evaluate the cost- effectiveness of three therapeutic schemes in the treatment of helicobacter pylori（Hp） infection.METHODS： A total of 441 cases with Hp infection were randomly divided into 3 groups： Group A was assigned to receive Rabeprazole ＋ clarithromycin ＋ Amoxicillin; Group B to receive Omepazole ＋ clarithromycin ＋ Timidazole, and Group C to receive Omepazole ＋ clarithromycin ＋ Amoxicillin.The curative effects of the 3 groups after treatment for lwk were compared and the cost - effectiveness analysis was conducted as well .RESULTS：The costs for the 3 schemes were 325.04 yuan, 221.30 yuan and 211.64 yuan, respectively; the Hp eradication rates of the three were 92.2%, 89.2% and 79.1%, re- spectively; the cost - effectiveness ratios were 352.54, 248.09 and 267.56 respectively; the increatmental cost - effectiveness ratios of Groups A and B were 865.65 and 95.64, respectively as against Group C.CONCLUSION：Group B is more economical and reasonable in the treatment of Hp infection.
出处
《中国药房》
CAS
CSCD
北大核心
2008年第2期84-85,共2页
China Pharmacy
关键词
奥美拉唑
幽门螺杆菌感染
治疗方案
成本-效果分析
Omepazole
Helicobacter pylori（Hp） infection
Therapeutic schemes
Cost - effectiveness analysis
